Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-03-16
2010-10-12
Robinson, Hope A (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000
Reexamination Certificate
active
07812132
ABSTRACT:
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5041376 (1991-08-01), Gething et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5225537 (1993-07-01), Foster
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5460950 (1995-10-01), Barr et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5648254 (1997-07-01), Mulvihill et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 5965425 (1999-10-01), Barr et al.
patent: 5986079 (1999-11-01), Barr et al.
patent: 6013620 (2000-01-01), Turecek et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6100061 (2000-08-01), Reiter et al.
patent: 6423826 (2002-07-01), Nelsestuen et al.
patent: 6475725 (2002-11-01), Reiter et al.
patent: 6693075 (2004-02-01), Nelsestuen
patent: 6747003 (2004-06-01), Nelsestuen
patent: 6762286 (2004-07-01), Nelsestuen
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6903069 (2005-06-01), Pingel et al.
patent: 2003/0100506 (2003-05-01), Nelsestuen
patent: 2003/0100740 (2003-05-01), Persson et al.
patent: 2003/0104978 (2003-06-01), Persson et al.
patent: 2003/0211094 (2003-11-01), Nelsestuen
patent: 2003/0211460 (2003-11-01), Nelsestuen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 512 011 (1992-11-01), None
patent: WO 88/10295 (1988-12-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 92/15686 (1992-09-01), None
patent: WO 94/27631 (1994-12-01), None
patent: WO 96/00577 (1996-01-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 99/03498 (1999-01-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 99/66031 (1999-12-01), None
patent: WO 00/26230 (2000-05-01), None
patent: WO 00/26354 (2000-05-01), None
patent: WO 00/28065 (2000-05-01), None
patent: WO 00/54787 (2000-09-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/83725 (2001-11-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
patent: WO 02/22776 (2002-03-01), None
patent: WO 02/29025 (2002-04-01), None
patent: WO 02/38162 (2002-05-01), None
patent: WO 02/077218 (2002-10-01), None
patent: WO 03/027147 (2003-04-01), None
patent: WO 03/037932 (2003-05-01), None
patent: WO 03/055512 (2003-07-01), None
patent: WO 03/093465 (2003-11-01), None
patent: WO 2004/029091 (2004-04-01), None
patent: WO 2004/083361 (2004-09-01), None
Persson et al. (FEBS Letters (May 1996) 385: 242-243).
Cheung et al. (Thromb. Res. (1995) 79(2): 199-206.
GenBank Accession No. M13232 (Hagen et al., 1986).
“Docking of Tissue Factor and Factor VIIa Initiates Blood Coagulation,” at http://www.sdsc.edu.IOTW/week46.96/ (1996).
Bharadwaj et al., “Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity,”J. Biol. Chem. 1996, 271:30685-30691.
Bjoern et al., “Human plasma and recombinant factor VII. Characterization of O-glycosylations serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine,”J. Biol. Chem. 1991, 266(17):11051-11057.
Chang et al., “Engineered recombinant factor VII Q217 variants with altered inhibitor specificities,”Biochemistry1999, 38:10940-10948.
Chang et al., “Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B,”J. Clin. Invest. 1997, 100(4), 886-892.
Cheung et al., “Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX,”Thrombosis Res. 1995, 80(5): 419-427.
EMBL Accession No. AF465270 (Feb. 2, 2003).
UNIPROT Accession No. P22457 (Aug. 1, 1991).
Dickinson et al., “Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa,”J. Mol. Biol. 1998, 277:959-971.
Dickinson et al., “Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa,”Proc. Natl. Acad. Sci. USA1996, 93:14379-14384.
Hedner et al., “NovoSeven as a universal haemostatic agent,”Blood Coagulation&Fibrinolysis2000:11:107-111.
Higashi et al., “Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity,”J. Biol. Chem. 1996, 271(43):26569-26574.
Huang et al., “Substrate Recognition by Tissue Factor-Factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X”J. Biol. Chem. 1996, 271(36):21752-21757.
Iakhiaev et al., “The Role of Catalytic Cleft & Exosite Residues of Factor VIIa for Complex Formation with Tissue Factor Pathway Inhibitor”Thromobsis&Haemostasis2001, 85:458-463.
Iino et al., “Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII,”Archives of Biochemistry and Biophysics1998, 352(2):182-192.
Jin et al., “Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity,”Biochemistry1999, 38:1185-1192.
Jin et al., “Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity,”J. Mol. Biol. 2001, 307:1503-1517.
Kelly et al., “Ca2+binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function,”J. Biol. Chem. 1997, 272(28):17467-17472.
Kemball-Cook et al., “Coagulation Factor VII Gln100Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function,”J. Biol. Chem. 1998, 273(14):8516-8521.
Leff, “Genetically stripped-down Factor VIII corrects bleeding disorder in homophiliac mice,”BioWorld Today1997, 8(209):1,6.
Leonard et al., “Activation and Active Site Occupation Alter Conformation in the Region of the First of Human Epidermal Growth Factor-like Domain of Human Factor VII,”J. Biol. Chem. 2000, 275(45):34894-34900.
Mayer, “Ultra-early hemostatic therapy for intracerebral hemorrhage,”Stroke2003, 34:224-229.
Nelsestuen, “Enhancement of Vitamin-K-Dependent Protein Function by Modification of the γ-Carboxyglutamic Acid Domain: Studies of Protein C and Factor VII,”Trends Cardiovasc. Med. 1999, 9:162-167.
Nelsestuen et al., “Vitamin K dependent proteins,”inVitamins and Hormones, Ed. Litwack, Academic Press, San Diego, CA, 2000, vol. 58, pp. 355-389.
Nelsestuen and Ostrowski, “Membrane association with multiple calcium ions: vitamin-K-dependent proteins, annexins and pentraxins,”Curr. Opin. Struct. Biol., 1999, 9:433-437.
Neuenschwander et al., “Alteration of the substrate and inhibitor specificities of blood coagulation,”Biochemistry1995, 34:8701-8707.
Osterlund et al., “Spectroscopic probing of the influence of calcium and the Gla domain
Fish & Richardson P.C.
Regents of the University of Minnesota
Robinson Hope A
LandOfFree
Modified vitamin K-dependent polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vitamin K-dependent polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vitamin K-dependent polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217229